Tebentafusp

Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100 -expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells. In Vitro Tebentafusp is an ImmTAC recognizing a peptide derived from the melanoma-specific protein, gp100, presented by HLA-A*0201. Tebentafusp (31 pM, 82 pM, and 131 pM; 16 h) stimulates cytotoxic degranulation activity of PBMC against Mel526 cells rather than gp100-negative A375 cells. Tebentafusp (100 pM; 0-50 h) mediates CD8 + T cell killing despite the presence of regulatory T cells via monitoring caspase 3/7 activation during 40-48 hr. Tebentafusp (100 pM; 0-80 h) triggers cytolysis of melanoma cells by CD4 + T cell subpopulations. Tebentafusp (1, 12, 31, 82, and 131 pM; 24 h or 96 h) increases granzyme B amount, and induces broad cytokine and chemokine release including in both CD4 + and CD8 + cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Tebentafusp (10 μg/kg; i.v.) inhibits tumor growth in mouse melanoma model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Liquid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet